No. | Sex | Age (y) | Pathological stage | Histological diagnosis | No antigen (IFN-γ, pg/ml) | No antigen (GM-CSF, pg/ml) | STEAP281-296 (IFN-γ, pg/ml) | STEAP281-296 (GM-CSF, pg/ml) | EZH295-109 (IFN-γ, pg/ml) | EZH295-109 (GM-CSF, pg/ml) | TT830-843 (IFN-γ, pg/ml) | TT830-843 (GM-CSF, pg/ml) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 61 | M1a IV | adenocarcinoma | < | < | 259.7 ± 74.6 | 749.4 ± 196.9 | 220.8 ± 175.3 | 968.5 ± 159.7 | 95.9 ± 9.2 | 545.7 ± 25.3 |
2 | M | 80 | T3N0M0 IIB | adenosquamous carcinoma | < | < | 320.5 ± 267.2 | 893.0 ± 355.6 | 565.7 ± 38.0 | 997.3 ± 27.4 | 985.1 ± 799.0 | 1267.8 ± 260.9 |
3 | F | 71 | T1aN0M0 IA | adenocarcinoma | 41.0 ± 5.0 | 35.8 ± 2.5 | 704.3 ± 502.5 | 516.0 ± 87.1 | 1030.0 ± 106.6 | 147.4 ± 55.7 | 1004.4 ± 451.3 | 620.8 ± 472.2 |
4 | M | 81 | T3N0M0 IIB | adenocarcinoma | < | < | 516.8 ± 0 | 206.0 ± 93.9 | 94.9 ± 0 | 65.9 ± 32.3 | 57.1 ± 25.1 | 77.9 ± 12.7 |
5 | M | 74 | T1bN0M0 IA | adenocarcinoma | < | < | 31.1 ± 0 | 135.4 ± 0 | 31.1 ± 20.1 | 34.8 ± 0 | 64.2 ± 0 | 31.2 ± 0 |
6 | F | 69 | T3N0M0 IIB | adenocarcinoma | < | < | 487.6 ± 444.3 | 474.9 ± 188.5 | 473.1 ± 354.0 | 389.3 ± 70.1 | 550.3 ± 118.1 | 917.4 ± 147.4 |
7 | M | 74 | T2aN0M0 IB | basaloid carcinoma | < | < | 189.7 ± 76.9 | < | 152.7 ± 57.5 | < | 203.9 ± 0 | 299.7 ± 278.1 |
8 | M | 71 | T1aN0M0 IA | adenocarcinoma | < | < | 173.7 ± 7.3 | 105.2 ± 49.9 | 54.3 ± 2.7 | 158.4 ± 56.7 | 91.4 ± 62.1 | 180.8 ± 1.7 |
9 | F | 56 | T2aN0M0 IB | adenocarcinoma | < | < | < | < | 134.7 ± 0 | < | 91.9 ± 0 | < |
10 | F | 60 | T1aN1M0 IIA | adenocarcinoma | < | < | < | 43.0 ± 38.3 | 44.2 ± 5.0 | 287.9 ± 337.1 | 234.3 ± 91.3 | 172.3 ± 58.3 |
11 | M | 32 | - | - | < | < | < | 440.6 ± 110.0 | < | 598.9 ± 105.1 | < | 301.8 ± 52.2 |
12 | M | 44 | - | - | < | < | 214.3 ± 50.6 | 122.5 ± 20.9 | 148.2 ± 18.1 | < | 492.7 ± 312.7 | 156.7 ± 39.0 |
13 | M | 38 | - | - | < | < | 180.1 ± 45.5 | 319.6 ± 64.7 | 190.4 ± 40.2 | 334.2 ± 57.1 | 246.8 ± 81.0 | 414.4 ± 115.1 |